Revolution Medicines reports Q4 EPS (63c), consensus (82c)

Reports Q4 revenue $15.3M, consensus $7.75M. "2022 saw the entry of our first two RAS Inhibitor candidates, RMC-6236 and RMC-6291 , into clinical development," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "For RMC-6236, initial pharmacokinetics, molecular, radiographic and tolerability/safety data provide encouraging evidence that we are dosing patients at clinically active and tolerated doses. Consistent with its preclinical profile, RMC-6236 has shown promising preliminary antitumor activity against multiple tumor types and genotypes. Combined with initial evidence of clinical activity for RMC-6291, we are encouraged that these data should have positive readthrough to our broad portfolio of RAS Inhibitors. "In addition, IND-enabling development of RMC-9805, a mutant-selective RAS Inhibitor drug candidate designed to target cancers driven by the KRASG12D mutation, is progressing toward first-in-human dosing mid-year. And we recently announced the advancement of RMC-0708, a mutant-selective inhibitor of the KRASQ61H cancer variant, into IND-enabling development.